vamorolone

Santhera closes on first approval for DMD drug vamorolone
Pharmaphorum
Fri, 10/13/23 - 10:23 am
Santhera
Duchenne Muscular Dystrophy
DMD
vamorolone
EMA
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
Thu, 03/16/23 - 09:49 am
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Duchenne muscular dystrophy’s progress so far in 2023
Clinical Trials Arena
Wed, 02/22/23 - 10:00 am
Duchenne Muscular Dystrophy
DMD
Santhera Pharmaceuticals
ReveraGen
vamorolone
Regenxbio
RGX-202
FDA accepts Santhera, ReveraGen’s vamorolone NDA to treat DMD
Pharmaceutical Business Review
Tue, 01/10/23 - 10:42 am
Santhera Pharmaceuticals
ReveraGen
vamorolone
Duchenne Muscular Dystrophy
FDA
Santhera seeks speedy FDA review of Duchenne drug vamorolone
Pharmaphorum
Fri, 10/28/22 - 10:26 am
Santhera
Duchenne Muscular Dystrophy
vamorolone
FDA
Buoyed by new data, Santhera preps filing for DMD drug vamorolone
Pharmaforum
Tue, 11/23/21 - 09:43 am
Santhera
DMD
Duchenne Muscular Dystrophy
idebenone
vamorolone
FDA
Months after axing a Duchenne program and laying off dozens, Santhera claims a win there with a different program
Endpoints
Tue, 06/1/21 - 11:43 am
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy
vamorolone
clinical trials
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
BioSpace
Tue, 11/3/20 - 09:29 pm
Jounce Therapeutics
vopratelimab
Santhera
vamorolone
Puldysa
Aurinia Pharmaceuticals
FOS
Santhera axes half its employees and sees CMO depart after PhIII DMD fail
Endpoints
Mon, 11/2/20 - 10:23 am
Santhera
reorganization
Duchenne Muscular Dystrophy
vamorolone
layoffs
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Fierce Biotech
Wed, 09/2/20 - 11:04 am
Santhera
vamorolone
Duchenne Muscular Dystrophy
Idorsia
ReveraGen
Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove
Endpoints
Tue, 08/27/19 - 11:01 pm
Santhera
Duchenne Muscular Dystrophy
clinical trials
vamorolone
RaveraGen